Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3003891A in pregnant women and infants
NCT03191383Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Jul 2017
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (4 arms), sponsored by GSK. Primary endpoints: Number of subjects with solicited local adverse events at 7 days, Number of subjects with solicited general adverse events at 7 days and 6 more. Planned start Jul 2017; status: withdrawn.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03191383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191383.